Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Research context
CAMP4 THERAPEUTICS CORPORATION appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
CalAmp Corp is currently in a long term uptrend where the price is trading 9.9% above its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Technology sector with a price to sales ratio of 1.1.
CalAmp Corp's total revenue sank by 8.9% to $88M since the same quarter in the previous year.
Its net income has increased by 99.7% to $-24K since the same quarter in the previous year.
Finally, its free cash flow grew by 307.0% to $7M since the same quarter in the previous year.
Based on the above factors, CalAmp Corp gets an overall score of 4/5.